Becton, Dickinson and PT Raised to $127.50 at ISI Group (BDX)
ISI Group raised their price objective on shares of Becton, Dickinson and (NYSE:BDX) from $126.50 to $127.50 in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock. ISI Group’s target price suggests a potential upside of 6.72% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays raised their price target on shares of Becton, Dickinson and from $112.00 to $115.00 in a research note on Monday, June 30th. They now have an “underweight” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Becton, Dickinson and in a research note on Friday, June 27th. They now have a $126.00 price target on the stock. Finally, analysts at SunTrust raised their price target on shares of Becton, Dickinson and from $128.00 to $138.00 in a research note on Monday, June 9th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $110.12.
Shares of Becton, Dickinson and (NYSE:BDX) traded down 0.26% during mid-day trading on Wednesday, hitting $119.47. 638,978 shares of the company’s stock traded hands. Becton, Dickinson and has a 52 week low of $96.73 and a 52 week high of $120.66. The stock has a 50-day moving average of $118.3 and a 200-day moving average of $114.5. The company has a market cap of $23.082 billion and a price-to-earnings ratio of 24.99.
Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.45 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.50 by $0.05. The company had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.09 billion. During the same quarter last year, the company posted $1.39 earnings per share. Becton, Dickinson and’s revenue was up 3.6% compared to the same quarter last year. On average, analysts predict that Becton, Dickinson and will post $6.25 earnings per share for the current fiscal year.
Becton Dickinson and Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.